Viva Biotech Holdings (VBIZF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Viva Biotech Holdings (VBIZF) trades at $0.1724 with AI Score 42/100 (Grade C). Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical companies globally. Market cap: $358M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VBIZF: VBIZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VBIZF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VBIZF: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Viva Biotech Holdings (VBIZF) Healthcare & Pipeline Overview
Viva Biotech Holdings, based in Shanghai, offers integrated drug discovery services, including structural biology, medicinal chemistry, and antibody development, to global biotech and pharmaceutical clients. With a focus on early-stage research and development, the company supports innovation in novel therapeutics and boasts a profit margin of 9.4%.
What Is the Investment Thesis for VBIZF?
Viva Biotech Holdings presents an investment opportunity within the biotechnology sector, driven by the increasing demand for outsourced drug discovery services. The company's comprehensive service offerings, spanning from early-stage research to preclinical development, position it as a valuable partner for biotech and pharmaceutical companies. With a market capitalization of $358M and a profit margin of 9.4%, Viva Biotech demonstrates financial stability and growth potential. Key value drivers include the expansion of its CDMO services and the growing adoption of innovative drug modalities like PROTACs and XDCs, where Viva Biotech has established specialized platforms. Ongoing catalysts include the increasing outsourcing trend in the pharmaceutical industry and the company's ability to secure long-term partnerships with leading biotech firms. However, potential risks include competition from other CROs and CDMOs, regulatory changes in the pharmaceutical industry, and fluctuations in research and development spending by pharmaceutical companies.
Based on FMP financials and quantitative analysis
VBIZF Key Highlights
Market Cap of $358M indicates a substantial presence in the biotechnology sector.
- Profit Margin of 9.4% demonstrates the company's ability to generate profits from its operations.
- Gross Margin of 37.4% reflects efficient cost management in service delivery.
- Return on Equity (ROE) of 5.9% suggests effective utilization of shareholder equity.
- Debt-to-Equity Ratio of 29.59 indicates a moderate level of financial leverage.
Who Are VBIZF's Competitors?
VBIZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IQV IQVIA Holdings Inc. | $256.05 | +2.72% | $42.2B | 74 |
| CRL Charles River Laboratories International, Inc. | $291.45 | +0.50% | $14.0B | 64 |
| WCG WCG | $349.92 | +0.00% | — | |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| MDXG MiMedx Group, Inc. | $4.45 | +2.53% | $649M | 90 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VBIZF's Key Strengths?
Comprehensive service offerings
- Specialized platforms for innovative drug modalities
- Experienced team of scientists
- Strong reputation for quality
What Are VBIZF's Weaknesses?
Reliance on outsourcing trends in the pharmaceutical industry
- Competition from larger CROs and CDMOs
- Geographic concentration in China
- Exposure to regulatory changes in the pharmaceutical industry
What Could Drive VBIZF Stock Higher?
Increasing outsourcing trends in the pharmaceutical industry are driving demand for Viva Biotech's services.
- Growing adoption of innovative drug modalities like PROTACs and XDCs is creating new opportunities for Viva Biotech.
- Potential strategic partnerships and acquisitions could expand Viva Biotech's service offerings and geographic reach.
- Expansion of CDMO services to capture a larger share of the pharmaceutical manufacturing market.
- Expansion into new therapeutic areas, such as neurodegenerative diseases and autoimmune disorders.
What Are the Key Risks for VBIZF?
Financial-distress signal — its Altman Z-Score of 1.26 sits in the distress zone (elevated bankruptcy risk).
- Economic downturns could affect pharmaceutical R&D spending and reduce demand for Viva Biotech's services.
- Increased competition from other CROs and CDMOs could put pressure on pricing and margins.
- Regulatory changes impacting drug development could increase costs and delays.
- Technological advancements could render existing services obsolete.
- The company's geographic concentration in China exposes it to political and economic risks.
What Are the Growth Opportunities for VBIZF?
- Expansion of CDMO Services: Viva Biotech has the opportunity to expand its contract development and manufacturing services (CDMO) to capture a larger share of the pharmaceutical manufacturing market. The global CDMO market is projected to reach $160.1 billion by 2028, growing at a CAGR of 6.9% from 2021 to 2028. By investing in additional manufacturing capacity and expanding its service offerings, Viva Biotech can attract new clients and increase its revenue stream. This expansion can be achieved within the next 3-5 years.
- Adoption of PROTACs and Molecular Glues: Viva Biotech can capitalize on the growing interest in PROTACs (proteolysis-targeting chimeras) and molecular glues as novel therapeutic modalities. The PROTAC market is expected to grow significantly in the coming years, driven by the potential of these molecules to target previously undruggable proteins. Viva Biotech's specialized PROTAC/molecular glue platform positions it as a key partner for companies developing these innovative therapies. This growth is expected to materialize over the next 5-7 years.
- Development of XDC Platforms: Viva Biotech's XDC (antibody-drug conjugate) platform offers a growth opportunity in the targeted cancer therapy market. XDCs combine the specificity of antibodies with the cytotoxic activity of drugs, allowing for targeted delivery of therapeutics to cancer cells. The XDC market is projected to reach $29.4 billion by 2028, growing at a CAGR of 17.3% from 2021 to 2028. Viva Biotech can expand its XDC platform services to support the development of novel cancer therapies. This expansion can be realized within the next 3-5 years.
- Strategic Partnerships and Acquisitions: Viva Biotech can pursue strategic partnerships and acquisitions to expand its service offerings and geographic reach. By partnering with complementary CROs and CDMOs, Viva Biotech can offer a more comprehensive suite of services to its clients. Acquisitions can also provide access to new technologies and markets. These partnerships and acquisitions can be pursued on an ongoing basis.
- Expansion into New Therapeutic Areas: Viva Biotech can expand its services into new therapeutic areas, such as neurodegenerative diseases and autoimmune disorders. By investing in research and development in these areas, Viva Biotech can attract new clients and diversify its revenue stream. This expansion can be achieved over the next 5-7 years.
What Are VBIZF's Competitive Advantages?
- Integrated service offerings: Provides a comprehensive suite of services, making it a one-stop shop for drug discovery needs.
- Specialized platforms: Offers specialized platforms for innovative drug modalities like PROTACs and XDCs.
- Experienced team: Has a team of experienced scientists and drug discovery experts.
- Established reputation: Has a strong reputation for providing high-quality services.
What Does VBIZF Do?
Viva Biotech Holdings, incorporated in 2008 and headquartered in Shanghai, China, is an investment holding company focused on providing structure-based drug discovery services to biotechnology and pharmaceutical clients worldwide. The company's services span the entire drug discovery process, starting from target identification and validation to lead optimization and preclinical development. Viva Biotech offers a comprehensive suite of services, including discovery biology, chemistry, and antibody/biologics research and development. Specifically, its discovery biology services encompass protein expression and purification, structural biology, hit discovery, bioassay development, biomolecular interaction analysis, and pharmacology and DMPK studies. The company's chemistry services include medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design. In the antibody/biologics area, Viva Biotech provides recombinant protein expression, antibody discovery and affinity maturation, assay platform development, antibody production and identification, and antigen-antibody structural resolution. Additionally, Viva Biotech offers specialized services in PROTAC/molecular glue development, including protein preparation, ternary complex structure determination, and PROTAC molecule design and synthesis. The company also provides XDC (antibody-drug conjugate) platform services, covering conjugation, quality studies, chemistry R&D, and functional studies. Beyond research, Viva Biotech offers contract development and manufacturing services (CDMO), including integrated services for small molecule active pharmaceutical ingredients (APIs), formulation development and production, pharmaceutical analysis, CMC filing, and global filing registration support. Viva Biotech's integrated service offerings position it as a key partner for biotech and pharmaceutical companies seeking to accelerate their drug discovery and development efforts.
What Products and Services Does VBIZF Offer?
- Provides structure-based drug discovery services.
- Offers discovery biology services including protein expression and structural biology.
- Delivers chemistry services such as medicinal and synthetic chemistry.
- Provides antibody/biologics research and development services.
- Offers PROTAC/molecular glue services.
- Provides XDC (antibody-drug conjugate) platform services.
- Offers contract development and manufacturing services (CDMO).
- Provides research services.
How Does VBIZF Make Money?
- Fee-for-service model: Charges clients for specific drug discovery services.
- Integrated service offerings: Provides a comprehensive suite of services from early-stage research to preclinical development.
- Partnerships: Collaborates with biotech and pharmaceutical companies to accelerate drug discovery efforts.
What Industry Does VBIZF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, proteomics, and personalized medicine. The market for outsourced drug discovery services is expanding, as pharmaceutical companies increasingly rely on contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to reduce costs and accelerate drug development timelines. Viva Biotech Holdings operates in this competitive landscape, offering a comprehensive suite of services to biotech and pharmaceutical clients. The global CRO market is projected to reach $84.8 billion by 2027, growing at a CAGR of 7.4% from 2020 to 2027. Viva Biotech is positioned to capitalize on this growth by providing integrated services and specialized platforms for innovative drug modalities.
Who Are VBIZF's Key Customers?
- Biotechnology companies
- Pharmaceutical companies
- Academic research institutions
Key Financial Metrics
Return on equity for Viva Biotech Holdings stands at 5.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.1%, showing how much profit it generates from its asset base. VBIZF trades at a trailing price-to-earnings ratio of 12.19, below the Healthcare sector average of ~23x. Its free cash flow yield is 3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.50 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.5%, the inverse of the P/E and a quick read on earnings relative to price.
Viva Biotech Holdings (VBIZF) Valuation Context
Valued at $358M, VBIZF is classified as a small-cap stock. Relative to its peer group, VBIZF's quantitative score of 42/100 is below the peer average of 71/100.
Company Profile
Viva Biotech Holdings operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Chen Cheney Mao. VBIZF has traded publicly since 2019.
Financial Health
Viva Biotech Holdings's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.26 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Viva Biotech Holdings revenue of about $2.20B for fiscal 2026, with EPS near $0.12.
VBIZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Comprehensive service offerings
- Specialized platforms for innovative drug modalities
- Experienced team of scientists
- Strong reputation for quality
Bear Case
- Reliance on outsourcing trends in the pharmaceutical industry
- Competition from larger CROs and CDMOs
- Geographic concentration in China
- Exposure to regulatory changes in the pharmaceutical industry
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
VBIZF Latest News
No recent news available for VBIZF.
VBIZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VBIZF.
Price Targets
Wall Street price target analysis for VBIZF.
VBIZF MoonshotScore
What does this score mean?
The MoonshotScore rates VBIZF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
VBIZF OTC Market Information
The OTC Other tier, where VBIZF trades, represents the lowest of the OTC Markets tiers. Companies in this tier may not meet minimum financial standards or may choose not to provide current information to the public markets. These securities are often speculative and carry a higher degree of risk compared to those listed on national exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC Tier: OTC Other
- Limited information disclosure: The lack of readily available financial information makes it difficult to assess the company's financial health and prospects.
- Low liquidity: The low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares quickly and at a favorable price.
- Price volatility: OTC stocks are generally more volatile than exchange-listed stocks, and investors may experience significant price fluctuations.
- Potential for fraud: The OTC market is less regulated than national exchanges, which increases the risk of fraud and manipulation.
- Going concern risk: Companies trading on the OTC Other tier may be facing financial difficulties or may not have a sustainable business model.
- Verify the company's registration and regulatory filings with the SEC or other relevant authorities.
- Obtain and review the company's financial statements, if available, and assess its financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the company's legal and regulatory risks.
- Determine the company's ownership structure and any potential conflicts of interest.
- Consult with a qualified financial advisor before making any investment decisions.
- Established operations: Viva Biotech has been in operation since 2008, indicating a degree of stability.
- Industry partnerships: The company's partnerships with biotech and pharmaceutical companies suggest a level of industry recognition.
- Comprehensive service offerings: The company's integrated service offerings demonstrate a breadth of capabilities.
- Global presence: The company's operations in China and its service to global clients indicate a wider reach.
Viva Biotech Holdings Healthcare Stock: Key Questions Answered
What does the AI Score mean for VBIZF?
VBIZF holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Viva Biotech Holdings provides structure-based drug discovery services to biotechnology and pharmaceutical companies globally. It offers a comprehensive suite of services, including discovery …
What does Viva Biotech Holdings do?
Viva Biotech Holdings is a contract research organization (CRO) and contract development and manufacturing organization (CDMO) that provides integrated drug discovery services to biotechnology and pharmaceutical companies worldwide. The company offers a comprehensive suite of services, spanning from early-stage research to preclinical development, including discovery biology, chemistry, antibody/biologics research and development, PROTAC/molecular glue services, XDC platforms, and CDMO services.
What do analysts say about VBIZF stock?
As of March 16, 2026, a comprehensive analyst consensus for VBIZF is not readily available due to its OTC market listing. However, key valuation metrics to consider include the company's market capitalization of $358M, profit margin of 9.4%, and gross margin of 37.4%.
What are the main risks for VBIZF?
The main risks for Viva Biotech Holdings include economic downturns affecting pharmaceutical R&D spending, increased competition from other CROs and CDMOs, regulatory changes impacting drug development, technological advancements rendering existing services obsolete, and the company's geographic concentration in China exposing it to political and economic risks.
What are the key factors to evaluate for VBIZF?
Viva Biotech Holdings (VBIZF) holds an AI score of 42/100 (low). P/E: 12.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does VBIZF data refresh on this page?
VBIZF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VBIZF's recent stock price performance?
Viva Biotech Holdings (VBIZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive service offerings. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VBIZF overvalued or undervalued right now?
Viva Biotech Holdings (VBIZF) trades at 12.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VBIZF before investing?
Before investing in Viva Biotech Holdings (VBIZF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and industry reports.
- OTC market data may be limited or delayed.